Stay updated on Upadacitinib vs Abatacept in RA Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib vs Abatacept in RA Clinical Trial page.

Latest updates to the Upadacitinib vs Abatacept in RA Clinical Trial page
- CheckyesterdayChange DetectedThe record presents details of a completed Phase 3 rheumatoid arthritis study comparing upadacitinib with abatacept, including its design, eligibility criteria, outcomes, and locations. It also includes study publications, protocol documents, and information on sharing participant-level data.SummaryDifference100%

- Check8 days agoChange DetectedThe ClinicalTrials.gov footer revision label changes from v3.7.2 to v3.8.0, while the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check15 days agoChange DetectedA site-wide NIH notice announces a transition from “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs. It appears above the ClinicalTrials.gov error page.SummaryDifference1%

- Check22 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check28 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe study page now shows a 403 Forbidden error for the record, indicating access restrictions. This replaces the previous study details with an error page.SummaryDifference18%

Stay in the know with updates to Upadacitinib vs Abatacept in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib vs Abatacept in RA Clinical Trial page.